Expanding Product Portfolio Sorrento Therapeutics is constantly expanding its product portfolio to address a wide range of diseases, including cancer, autoimmune, inflammatory, and viral diseases. This breadth of offering presents multiple sales opportunities for partnering with hospitals, clinics, and pharmaceutical distributors.

Focus on COVID-19 Solutions With a focus on developing therapies and diagnostic solutions for COVID-19, Sorrento Therapeutics has positioned itself as a key player in the global pandemic response. Sales professionals can leverage this specialized expertise to engage with government agencies, healthcare facilities, and research institutions seeking innovative COVID-19 solutions.

Recent Acquisitions and Collaborations Through recent acquisitions and collaborations, such as acquiring Virax Health and securing financing through partnerships, Sorrento Therapeutics has expanded its capabilities and resources. Sales representatives can explore partnership opportunities with Sorrento to tap into their extended network and expertise.

Positive Clinical Study Findings Recent positive findings from clinical studies, such as the phase IIa study on Abivertinib, showcase Sorrento's commitment to innovation and product efficacy. Sales professionals can utilize this data to engage with healthcare providers and demonstrate the value of Sorrento's therapeutic solutions.

Legal Developments and Funding Keeping abreast of legal developments, such as the dismissal of a securities fraud suit and successful debtor-in-possession financing, indicates Sorrento's financial resilience and legal standing. Sales development representatives can leverage this information to build trust with potential partners and investors.